July 19, 2021
“Ambrx Biopharma (AMAM)… This new biopharma stock has a Strong Buy rating from the analyst consensus, based on 3 positive reviews so far. The shares are priced at $19.56 and their $39.50 average target suggests room for an upside of 101%… Continue Reading…
July 13, 2021
“A Bonanza Of Profit Is Coming Analysts see 1,000% or more profit growth from these S&P 500 companies in the second quarter Company Ticker Q2 EPS % Ch. Primary Sector Composite Rating % stock YTD ch. Zimmer Biomet (ZBH) 3,620.0%… Continue Reading…
July 13, 2021
“TaskUs (TASK)… This newly public stock has attracted no fewer than 9 analyst reviews in its short time on the public markets. Those reviews break down 8 to 1 in favor of the Buy over Hold, giving TASK a Strong Buy… Continue Reading…
July 13, 2021
“Baidu (NASDAQ: BIDU)… …Overall, 17 Wall Street analysts have weighed in on Baidu shares in the past three months, giving the stock 14 Buys and 3 Holds for a Strong Buy consensus rating. The average Baidu price target of $304.40 implies approximately 67.8% upside… Continue Reading…
July 12, 2021
“Evolent Health (EVH)… Overall, this stock has 5 recent analyst reviews on file, and they break down 4 to 1 in favor the Buys over the Hold. The shares are currently trading for $22.79 and have an average price target… Continue Reading…
July 12, 2021
“Goldman Sachs… According to TipRanks’ stock analysis, GS receives a Smart Score of 9, meaning the stock is likely to Outperform. The Smart Score is derived from 8 unique data sets, including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment… Continue Reading…
July 12, 2021
“Warren Buffett stocks are famous for their tight focus. And this year the famed investor’s highly concentrated play on a few top S&P 500 stocks is paying off. Just three top U.S.-listed stocks in Berkshire Hathaway‘s (BRKB) portfolio, information technology giant Apple (AAPL) plus financials Bank of… Continue Reading…
July 9, 2021
“Annaly Capital Management (NLY)… The Wall Street decision on Annaly is an even split, with 3 recent Buy recommendations and 3 to Hold, giving the stock a Moderate Buy consensus rating. The shares are priced at $8.71 with an average… Continue Reading…
July 9, 2021
“Aerpio Pharmaceuticals (ARPO) is a biopharmaceutical company focused on developing compounds that activate Tie2. Tie2 is considered a key regulator of vascular stability, and ARPO “believes that activation of Tie2 may have therapeutic potential” for different indications. In Q1, ARPO… Continue Reading…
July 7, 2021
“BioHiTech Global, Inc. (BHTG)… In line with these comments, Dayal rates the stock as a Buy, and his $4 price target implies robust growth of 181% for the next 12 months. Dayal’s review is the only one file for BHTG shares,… Continue Reading…
Recent Comments